-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$39.50-1.25% Downside
Calliditas Therapeutics AB (publ) Frequently Asked Questions
-
What analysts cover Calliditas Therapeutics AB (publ)?
Calliditas Therapeutics AB (publ) has been rated by research analysts at Jefferies, Stifel Nicolaus in the past 90 days.